Stumbles by several top biotech names are weighing on the iShares NASDAQ Biotechnology Index (ETF) IBB 1.57% on Wednesday.
- Eli Lilly and Co LLY 2.78% shares are down 11.4 percent following news that the company’s drug solanezumab came up short of its primary endpoint for treatment of mild Alzheimer dementia.
- Juno Therapeutics Inc JUNO 3.87% shares are down 26.9 percent after the company announced the suspension of its JCAR015 Phase II ROCKET trial following two cases of cerebral edema in patients.
- Cellectar Biosciences Inc CLRB 3.03% shares plummeted 29.6 percent on news of an $8 million public offering.
Despite the bad news, the IBB ETF has been surprisingly resilient on Wednesday, down just 0.2 percent in mid-day trading. Biotech stocks have witnessed a huge relief rally following Hillary Clinton’s loss on Election Day. The IBB is up 7 percent since November 8.
Clinton had made drug pricing a central issue of her platform. While drug companies aren’t yet certain of what they will be getting with Trump in the White House, they have at least dodged…
Click here to continue reading
Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!